{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:29:06Z","timestamp":1761488946242},"reference-count":0,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[1990,9,1]],"date-time":"1990-09-01T00:00:00Z","timestamp":652147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1990,9]]},"abstract":"<jats:p>Disseminated Mycobacterium avium infection is the major cause of bacteremia in patients with acquired immunodeficiency syndrome. We present here a new animal model of this disease, thymectomized C57BL\/6 mice that were intravenously infused with monoclonal antibody to selectively deplete CD4+ T cells. The increased susceptibility of such animals to M. avium infection is comparable to that of C57BL\/6 beige mice and thus may provide a viable alternative to the latter model. Further, using representative strains of acquired immunodeficiency syndrome-associated M. avium (serotypes 1, 4, and 8 and a rough isolate), we show that the course of such infections in thymectomized, CD4-deficient mice can be markedly restrained and in some cases the infections can be sterilized by treatment over a 120-day period with a regimen containing 40 mg of the new antimycobacterial agent rifabutin per kg (body weight).<\/jats:p>","DOI":"10.1128\/aac.34.9.1629","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"1629-1632","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice"],"prefix":"10.1128","volume":"34","author":[{"given":"S K","family":"Furney","sequence":"first","affiliation":[{"name":"Department of Microbiology, Colorado State University, Fort Collins 80523."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Colorado State University, Fort Collins 80523."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I M","family":"Orme","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Colorado State University, Fort Collins 80523."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.34.9.1629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.34.9.1629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:18:04Z","timestamp":1645456684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.34.9.1629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,9]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1990,9]]}},"alternative-id":["10.1128\/AAC.34.9.1629"],"URL":"https:\/\/doi.org\/10.1128\/aac.34.9.1629","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,9]]},"assertion":[{"value":"1990-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}